Intech Biopharm Corporation (TPEX:6461)
18.30
-0.30 (-1.61%)
Mar 24, 2026, 1:24 PM CST
Intech Biopharm Revenue
Intech Biopharm had revenue of 7.28M TWD in the quarter ending September 30, 2025, a decrease of -15.89%. This brings the company's revenue in the last twelve months to 113.85M, up 234.15% year-over-year. In the year 2024, Intech Biopharm had annual revenue of 39.78M with 53.90% growth.
Revenue (ttm)
113.85M
Revenue Growth
+234.15%
P/S Ratio
26.19
Revenue / Employee
1.27M
Employees
90
Market Cap
2.98B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 39.78M | 13.93M | 53.90% |
| Dec 31, 2023 | 25.85M | 2.20M | 9.30% |
| Dec 31, 2022 | 23.65M | -15.25M | -39.21% |
| Dec 31, 2021 | 38.90M | 17.79M | 84.30% |
| Dec 31, 2020 | 21.11M | 4.42M | 26.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Syngen Biotech | 2.14B |
| Apex Biotechnology | 1.94B |
| SYN-TECH Chem. & Pharm. | 1.30B |
| Genovate Biotechnology | 492.41M |
| Sagittarius Life Science | 346.08M |
| HeXun Biosciences | 290.83M |
| GlycoNex Incorporation | 37.86M |
| ACRO Biomedical | 36.50M |